Fibromyalgia survey needs your help
The National Fibromyalgia & Chronic Pain Association has a new survey and needs more participants. The voluntary survey is anonymous, and results will be used to advocate better for patients suffering from chronic pain. The organization is concerned about how new government regulations for opioid medications are affecting fibromyalgia patients.
The National Fibromyalgia & Chronic Pain Association (NFMCPA) is looking for patients who take prescription hydrocodone medications. The survey is available online and will close on March 8. The NFMCPA is a nonprofit 501(c)(3)charitable organization, and it is worried that the new guidelines are making access to pain medication more difficult for chronic pain sufferers.
The National Fibromyalgia & Chronic Pain Association explains that hydrocodone is now classified as a Schedule II drug instead of Schedule III. Stricter guidelines are in place such as forcing patients to sign contracts with doctors related to pain medication use. In addition, prescriptions must be hand-signed by doctors, and appointments have to be made monthly. The organization wants fibromyalgia patients to share how these guidelines are affecting them in a survey.
The survey is confidential and anonymous, and the NFMCPA promises data will be stored securely. You must be at least 18 years old to participate. In addition, you must have taken hydrocodone medication such as Vicodin or Lorcet to take part in the study. Questions range from describing medical chronic pain diagnoses to sharing the type of health insurance you use.
The survey, titled Hydrocodone Rescheduling: The First 100 Days, is part of a planned series from the National Fibromyalgia & Chronic Pain Association. The organization is concerned that stricter guidelines created to diminish drug abuse are hurting patients with valid chronic pain issues. It hopes the results from the survey will give patients an important voice that is often ignored by the medical community.
Read more about fibromyalgia:
Memantine drug shows promise for fibromyalgia
Fibromyalgia study focuses on brain stimulation to fight pain